Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 2014 Anthera Pharmaceuticals, Inc. (Nasdaq: ... , President and Chief Executive Officer, will present a ... Conference. Anthera will present at 4:30PM ... in New York City . ... is a biopharmaceutical company focused on developing and commercializing ...
(Date:11/22/2014)... de noviembre de 2014  BioClinica®, Inc., un ... y tecnologías eClinical, ha indicado un aumento de ... para el seguimiento basado en el riesgo en ... concepto del seguimiento basado en el riesgo más ... de seguimiento o cambio de los métodos de ...
(Date:11/22/2014)... 2014 Research and Markets  has announced the ... Report, 2014-2017" report to their offering. ... recombinant protein drug market has been expanding rapidly owing ... the like. During 2005-2013, sales of recombinant protein drugs ... of 19.1%, and it is projected that ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3
... Studies in Mice Show Reduction of Enzyme ... -- Amicus,Therapeutics, a biopharmaceutical company developing,small-molecule, orally ... genetic diseases, announced today that the,Company will ... AT1001), Amicus' compound in development for the,treatment ...
... 2007 - Avid,Radiopharmaceuticals, Inc. (Avid), a product-focused ... the first,results from a clinical study of ... tomography (PET) imaging,of amyloid plaques in patients ... from Austin Hospital of,Melbourne, a leading investigator ...
Cached Medicine Technology:Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease 2Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease 3Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting 2Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting 3Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting 4
(Date:11/24/2014)... Houston, TX (PRWEB) November 24, 2014 ... in all of the wrong ingredients. Consistently consuming a ... body to develop stores of excess fat that typically ... health problems and rearing its ugly head in the ... , When dieters make the decision to rid ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
(Date:11/24/2014)... Diego, California (PRWEB) November 24, 2014 Dr. ... San Diego Fertility Center, recently appeared on NBC to discuss ... option. Egg freezing has been trending in the news recently, ... this expensive procedure for women. , “[The companies] ... women who are on a career hot path.” Says Dr. ...
(Date:11/23/2014)... November 24, 2014 The clinical ... 2014" provides data on the Aspergillosis clinical trial ... relating to the clinical trials on Aspergillosis. It ... their recruitment status as per the site of ... a preliminary coverage of disease clinical trials by ...
(Date:11/23/2014)... 24, 2014 For the coming special ... has launched a great promotion for many products, especially ... can get the best choice with amazing discounts, up ... Tidebuy.com. , It is easy to buy colored ... that, this selection is also famous for delicate craftsmanship, ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2
... now infarct size has only been measured as part of ... being that the reference method of gadolinium based contrast agents ... to perform, and can only be undertaken by imaging specialists," ... Padua, Italy. "The advantages of STE over MRI is that ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- Working ... may also increase your risk of developing type 2 diabetes, new ... found that those who worked rotating night shifts were more likely ... the longer that they worked a rotating shift schedule, the greater ...
... TX - Accelerated partial breast irradiation (APBI) brachytherapy, ... popular as a treatment choice for women with ... of later mastectomy, increased radiation-related toxicities and post-operative ... according to researchers from The University of Texas ...
... Denise Mann HealthDay Reporter , TUESDAY, Dec. 6 ... for preterm birth as early as 23 weeks during their ... reduce the baby,s risk of serious developmental issues, including brain ... the Dec. 7 issue of the Journal of the ...
... , TUESDAY, Dec. 6 (HealthDay News) -- U.S. ... remove controversial, unapproved and illegally labeled HCG weight loss products ... a hormone made by the human placenta and found in ... in conjunction with an extremely low-calorie diet -- as low ...
... Reinberg HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay ... with hormone therapy do not appear to be at increased ... new review of evidence. Hormone therapy called "androgen ... previous studies found that the therapy might increase the risk ...
Cached Medicine News:Health News:Echocardiography offers the future for infarct size quantification 2Health News:Echocardiography offers the future for infarct size quantification 3Health News:Echocardiography offers the future for infarct size quantification 4Health News:Rotating Shift Work May Boost Women's Diabetes Risk 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 3Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 2Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 3Health News:Steroids May Boost Survival for Very Preemie Babies 2Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: